All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Sébastien Anguille from the Antwerp University Hospital and University of Antwerp, Antwerp, Belgium, et al. reported results of their phase II study (NCT00965224), which aimed to evaluate the therapeutic efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated autologous Dendritic Cell (DC) vaccination in patients with Acute Myeloid Leukemia (AML) in Blood on 22nd August 2017.
Overall, 30 AML patients (median age = 65 years) in remission after chemotherapy who were at high-risk of relapse were vaccinated intradermally with autologous DCs loaded with WT1 antigen by means of mRNA electroporation (allows human leukocyte antigen haplotype-independent multi-epitope presentation to T-cells).
In summary, vaccination of AML patients in remission with WT1 mRNA-electroporated DCs lead to improved OS rates, which correlated with the induction of WT1-specific CD8+ T-cell responses.
The authors concluded by proposing that vaccination with WT1/DCs should be considered as a “non-toxic, post-remission strategy to prevent or delay relapse of AML in an adjuvant setting”.
Relapse is a major problem in acute myeloid leukemia (AML) and adversely impacts survival. In this phase II study, we investigated the effect of vaccination with dendritic cells (DCs) electroporated with Wilms' tumor 1 (WT1) mRNA as post-remission treatment in 30 AML patients at very high risk of relapse. There was a demonstrable anti-leukemic response in 13 patients. Nine patients achieved molecular remission as demonstrated by normalization of WT1 transcript levels, 5 of which are sustained after a median follow-up of 109.4 months. Disease stabilization was achieved in 4 other patients. Five-year overall survival (OS) was higher in responders than in non-responders (53.8% vs. 25.0%; P=0.01). In patients receiving DCs in first complete remission (CR1), there was a vaccine-induced relapse reduction rate of 25% and the 5-year relapse-free survival was higher in responders than in non-responders (50% vs. 7.7%; P<0.0001). In patients ≤65 and >65 years who received DCs in CR1, 5-year OS was 69.2% and 30.8% respectively, as compared to 51.7% and 18% in the Swedish Acute Leukemia Registry (SALR). Long-term clinical response was correlated with increased circulating frequencies of poly-epitope WT1-specific CD8+ T-cells. Long-term OS was correlated with interferon-γ+ and tumor necrosis factor-α+ WT1-specific responses in delayed type hypersensitivity-infiltrating CD8+ T-lymphocytes. In conclusion, vaccination of AML patients with WT1 mRNA-electroporated DCs can be an effective strategy to prevent or delay relapse after standard chemotherapy, translating into improved OS rates, which are correlated with the induction of WT1-specific CD8+ T-cell response. This trial was registered at www.clinicaltrials.gov as #NCT00965224.
Subscribe to get the best content related to AML delivered to your inbox